MONOGRAM BIOSCIENCES AND MERCK TO CONDUCT ERBITUX(R) BIOMARKER STUDY

Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (Xetra: Merck KGaA) to conduct a cancer biomarker study with application to Erbitux(R)(cetuximab), Merck KGaA's IgG1 monoclonal antibody specifically targeting the epidermal growth factor receptor (EGFR) found on many cancer cells.
PR Newswire